Status:

WITHDRAWN

The Effect of T89 on Improving Oxygen Saturation and Clinical Symptoms in Patients With COVID-19

Lead Sponsor:

Tasly Pharmaceuticals, Inc.

Conditions:

Coronavirus Disease 2019

Novel Coronavirus Pneumonia

Eligibility:

All Genders

18-85 years

Phase:

NA

Brief Summary

This is an open-label, randomized, blank-controlled treatment clinical study. The objective of this study is to investigate the effect of T89 on improving oxygen saturation and clinical symptoms in pa...

Detailed Description

The breakout of a new type of coronavirus (SARS-CoV-2) begun in Wuhan of Hubei province in China in December 2019, and as a result of its rapid spreading nationwide, as of February 16, 2020, a large n...

Eligibility Criteria

Inclusion

  • Adult male or female patients aged 18-85 years old;
  • The newly diagnosed COVID-19 patients who meet the diagnostic criteria set forth in the "Guidance of Diagnosis and Treatment for Patients with Coronavirus Disease 2019 (COVID-19) (Procedural Version 5 Amendment)", issued by the National Health Commission of the People's Republic of China on 8 February 2020;
  • Patients whose blood oxygen saturation is not less than 90%.
  • Patients who agree to participate in the study and voluntarily comply with the relevant requirements of the study.

Exclusion

  • Patients with other diseases that may affect, in the opinion of study researchers, the implementation of the study or the observation of the efficacy data;
  • Patients with severe Coronavirus Disease 2019 (COVID-19), that is based on "Guidance of Diagnosis and Treatment for Patients with Coronavirus Disease 2019 (COVID-19) (Procedural Version 5 Amendment)" with respect to the criteria for clinical severity classification;
  • Female patients with known pregnancy and in lactation at screening;
  • Patients with previous allergies to T89 or Radix Salvia Miltiorrhizae, Radix Notoginseng and Borneol;
  • Any other condition that, in the opinion of the investigator, may affect the conduct of the study, reduce compliance or increase the risk of patients.

Key Trial Info

Start Date :

February 26 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

April 20 2020

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT04285190

Start Date

February 26 2020

End Date

April 20 2020

Last Update

June 16 2020

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.